Literature DB >> 11093813

Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer.

H Maacke1, S Opitz, K Jost, W Hamdorf, W Henning, S Krüger, A C Feller, A Lopens, K Diedrich, E Schwinger, H W Stürzbecher.   

Abstract

Breast cancer is a major cause of cancer-related death in women. BRCA1 tumour-suppressor function is abolished in sporadic breast cancer by down-regulation of the protein level. This down-regulation inversely correlates with tumour grading. BRCA1 is part of a multiprotein complex, which also contains the recombination factor Rad51. Here we describe that in contrast to BRCA1, histological grading of sporadic invasive ductal breast cancer significantly correlates with over-expression of wild-type Rad51. These data suggest that in addition to the absence of the tumour-suppressor protein BRCA1, over-expression of wild-type Rad51 also contributes to the pathogenesis of a significant percentage of sporadic breast cancers and that other mechanisms than mutations must be responsible for this altered expression. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11093813     DOI: 10.1002/1097-0215(20001215)88:6<907::aid-ijc11>3.0.co;2-4

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  77 in total

1.  Methotrexate-mediated inhibition of RAD51 expression and homologous recombination in cancer cells.

Authors:  Li-Qing Du; Xiao-Qing Du; Jian-Qiang Bai; Yan Wang; Qing-Shan Yang; Xiao-Chun Wang; Peng Zhao; Hong Wang; Qiang Liu; Fei-Yue Fan
Journal:  J Cancer Res Clin Oncol       Date:  2012-01-25       Impact factor: 4.553

2.  Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening.

Authors:  Fei Huang; Nuzhat A Motlekar; Chelsea M Burgwin; Andrew D Napper; Scott L Diamond; Alexander V Mazin
Journal:  ACS Chem Biol       Date:  2011-03-23       Impact factor: 5.100

3.  Rad51 promoter-targeted gene therapy is effective for in vivo visualization and treatment of cancer.

Authors:  Christopher M Hine; Andrei Seluanov; Vera Gorbunova
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

4.  Multipotent hematopoietic cells susceptible to alternative double-strand break repair pathways that promote genome rearrangements.

Authors:  Richard Francis; Christine Richardson
Journal:  Genes Dev       Date:  2007-05-01       Impact factor: 11.361

Review 5.  The consequences of Rad51 overexpression for normal and tumor cells.

Authors:  Hannah L Klein
Journal:  DNA Repair (Amst)       Date:  2008-02-01

6.  Enhanced PAPSS2/VCAN sulfation axis is essential for Snail-mediated breast cancer cell migration and metastasis.

Authors:  Yihong Zhang; Xiuqun Zou; Wenli Qian; Xiaoling Weng; Lin Zhang; Liang Zhang; Shuang Wang; Xuan Cao; Li Ma; Gang Wei; Yingjie Wu; Zhaoyuan Hou
Journal:  Cell Death Differ       Date:  2018-06-28       Impact factor: 15.828

Review 7.  Targeting the homologous recombination pathway by small molecule modulators.

Authors:  Fei Huang; Alexander V Mazin
Journal:  Bioorg Med Chem Lett       Date:  2014-05-06       Impact factor: 2.823

8.  DNA repair by homologous recombination, but not by nonhomologous end joining, is elevated in breast cancer cells.

Authors:  Zhiyong Mao; Ying Jiang; Xiang Liu; Andrei Seluanov; Vera Gorbunova
Journal:  Neoplasia       Date:  2009-07       Impact factor: 5.715

9.  Overexpression of RAD51 occurs in aggressive prostatic cancer.

Authors:  Anita Mitra; Charles Jameson; Yolanda Barbachano; Lydia Sanchez; Zsofia Kote-Jarai; Susan Peock; Nayanta Sodha; Elizabeth Bancroft; Anne Fletcher; Colin Cooper; Douglas Easton; Rosalind Eeles; Christopher S Foster
Journal:  Histopathology       Date:  2009-12       Impact factor: 5.087

10.  Overexpression of Drosophila Rad51 protein (DmRad51) disrupts cell cycle progression and leads to apoptosis.

Authors:  Siuk Yoo; Bruce D McKee
Journal:  Chromosoma       Date:  2004-07-15       Impact factor: 4.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.